Drug intelligence / Profile preview

SFG-02

Development stage: Phase 1
Lead developer: Juro Sciences
Modality: Small Molecules
Administration: Transdermal

Overview

SFG-02 is a **novel small molecule acetylcholinesterase inhibitor** developed by Juro Sciences for the treatment of **underactive bladder (UAB)**. It features a transformative **transdermal drug delivery system**, designed to maximize efficacy and minimize side effects. Preclinical studies demonstrated high selectivity for its molecular target and optimal efficacy in animal models of UAB. Nonclinical toxicology and ADME data support its initiations into clinical trials. Phase 1 clinical studies are underway to assess safety, tolerability, and pharmacokinetics in healthy adult volunteers[1][2][3][4][5][7][9]. The program is supported by grants from the Japan Agency for Medical Research and Development (AMED).

Brand names: SFG-02SFG02SFG 02
Other names: SFG-02SFG02SFG 02

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on SFG-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SFG-02.

Explore the full profile